title: Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
abstract: BACKGROUND
  Enoxaparin has gained wide acceptance in patients with acute coronary syndromes. However, there is uncertainty regarding management of patients who require coronary intervention while on enoxaparin. Some physicians withhold the morning dose of enoxaparin prior to coronary intervention while others switch patients to unfractionated heparin. Both methods do not provide optimal anticoagulation in the hours preceding intervention. There are no published controlled data to assess the safety of coronary intervention using enoxaparin alone in patients with acute coronary syndromes.
  
  
  METHODS
  We prospectively compared enoxaparin to unfractionated heparin during coronary angiography and intervention. Sixty four patients admitted to the coronary care unit (CCU) were given enoxaparin twice daily, including on the morning of procedure. Coronary angiography and intervention were performed without additional unfractionated heparin. The control group comprised of 52 patients admitted to Internal Medicine for an acute coronary syndrome. These were also given enoxaparin but the morning dose was withheld and unfractionated heparin was used during procedure.
  
  
  RESULTS
  Patients in both groups had similar baseline characteristics. No significant differences were observed between the two groups in procedural success rate, complications or bleeding. One year follow up showed similar rates of hospitalization and mortality.
  
  
  CONCLUSIONS
  Enoxaparin seems to offer safe and effective procedural anticoagulation in patients undergoing percutaneous intervention for acute coronary syndromes. Patients given enoxaparin can probably have coronary intervention without interruption of enoxaparin treatment and without additional procedural anticoagulation. These findings require confirmation in larger, randomized trials.
authors.affiliation: Department of Cardiology, Soroka Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, P.O. Box 151, 84101 Beer Sheva, Israel.
authors.forename: Arik
authors.initials: A
authors.lastname: Wolak
authors.forename: Yosef
authors.initials: Y
authors.lastname: Ayzenberg
authors.forename: Carlos
authors.initials: C
authors.lastname: Cafri
authors.forename: Harel
authors.initials: H
authors.lastname: Gilutz
authors.forename: Reuben
authors.initials: R
authors.lastname: Ilia
authors.forename: Doron
authors.initials: D
authors.lastname: Zahger
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000925:Anticoagulants / Q000627:therapeutic use; D017023:Coronary Angiography / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000628:therapy*; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D013923:Thromboembolism / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D006493:Heparin